Glembatumumab vedotin

製品コードD4054 別名: CDX-011 (DOX), CR011,CR011-vcMMAE 純度：99%

Glembatumumab vedotin (CDX-011 (DOX), CR011,CR011-vcMMAE) is an antibody-drug conjugate (ADC) composed of an fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB), conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Glembatumumab vedotin has the potential for use in research of Breast cancer (TNBC) and advanced or metastatic melanoma.

CAS No. 1182215-65-1

サイズ	価格(税別)	在庫状況
1mg	JPY 145500	国内在庫あり
1mg*5	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

クリックしてGlembatumumab vedotinの関連製品を購入する

質量管理及び製品安全説明書

現在のバッチを見る：純度： 99% タンパク質濃度： 3.42 mg/ml 内毒素：＜1EU/mg

生物活性

製品説明	Glembatumumab vedotin (CDX-011 (DOX), CR011,CR011-vcMMAE) is an antibody-drug conjugate (ADC) composed of an fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB), conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Glembatumumab vedotin has the potential for use in research of Breast cancer (TNBC) and advanced or metastatic melanoma.

製品説明

参考
https://pubmed.ncbi.nlm.nih.gov/30690710/ https://pubmed.ncbi.nlm.nih.gov/22229970/

参考

https://pubmed.ncbi.nlm.nih.gov/30690710/
https://pubmed.ncbi.nlm.nih.gov/22229970/

製品説明

CAS No.	1182215-65-1
Formulation	1xPBS
ADC antiody	Glembatumumab
ADC cytotoxin	MMAE
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping	Shipped under low temperature conditions

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02363283	COMPLETED	Drug: Glembatumumab Vedotin	Recurrent Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7	National Cancer Institute (NCI)	2015-09-16	PHASE2
NCT02302339	TERMINATED	Drug: glembatumumab vedotin\|Drug: glembatumumab vedotin and	Melanoma	Celldex Therapeutics	2014-11	PHASE2
NCT02713828	TERMINATED	Drug: Phase I: Glembatumumab Vedotin\|Drug: Phase II: Glembat	Squamous Cell Carcinoma of the Lung	PrECOG, LLC.	2016-04-10	PHASE1; PHASE2
NCT03473691	WITHDRAWN	Drug: Glembatumumab Vedotin	Triple Negative Breast Cancer	University of Virginia	2018-05-01	EARLY_PHASE1
NCT03326258	WITHDRAWN	Drug: Glembatumumab Vedotin	Advanced Malignant Solid Neoplasm; Estrogen Receptor Negative; GPNMB Positive; HER2/Neu Negative; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Progesterone Receptor Negative; Stage III Breast Cancer AJCC v7; Stage III Cutaneous Melanoma AJCC v7; Stage III Uveal Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IV Uveal Melanoma AJCC v7; Triple-Negative Breast Carcinoma; Unresectable Solid Neoplasm	National Cancer Institute (NCI)	2018-04-20	PHASE1; PHASE2
NCT02487979	COMPLETED	Drug: Glembatumumab Vedotin	Recurrent Osteosarcoma	National Cancer Institute (NCI)	2016-02-16	PHASE2

(data from https://clinicaltrials.gov, updated on 2020-08-21)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須